Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Casodex: preclinical studies.

B J Furr1

  • 1Bioscience 1, ICI Pharmaceuticals, Macclesfield, Cheshire, UK.

European Urology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

New antiandrogen Casodex offers a potent, selective treatment for advanced prostate cancer. Its long half-life and once-daily dosing suggest effective monotherapy with improved tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonsteroidal progestins and antiprogestins related to flutamide.

Steroids·2000
Same author

Relative potency of bicalutamide (Casodex) and flutamide (Eulexin)

Urology·1999
Same author

Bicalutamide ('Casodex') development: from theory to therapy.

The cancer journal from Scientific American·1997
Same author

Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.

European urology·1997
Same author

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.

Urology·1996
Same author

The development of Casodex (bicalutamide): preclinical studies.

European urology·1996
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced prostate cancer treatment often involves antiandrogens.
  • Current antiandrogens face challenges including short half-lives and non-selectivity, causing fluctuating hormone levels.
  • Non-selectivity can lead to increased luteinizing hormone (LH) and testosterone via central mechanisms.

Purpose of the Study:

  • To evaluate the efficacy and properties of Casodex, a novel pure antiandrogen.
  • To assess Casodex's potential as a monotherapy for advanced prostate cancer.

Main Methods:

  • Pre-clinical studies assessed Casodex's half-life and peripheral selectivity.
  • Efficacy was compared to surgical castration and Zoladex in a rat Dunning prostate tumor model.

Main Results:

Related Experiment Videos

  • Casodex demonstrated a long half-life and high peripheral selectivity in pre-clinical studies.
  • Casodex showed comparable efficacy to surgical or medical castration in inhibiting tumor growth.
  • These findings suggest Casodex is a potent antiandrogen.

Conclusions:

  • Casodex exhibits favorable pharmacokinetic and pharmacodynamic properties for prostate cancer treatment.
  • Once-daily administration of Casodex shows promise as an effective and well-tolerated monotherapy.
  • Casodex represents a potential advancement in managing advanced prostate cancer.